Hennion & Walsh Asset Management Inc. Sells 4,348 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Hennion & Walsh Asset Management Inc. lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,957 shares of the company’s stock after selling 4,348 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $1,360,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Intellectus Partners LLC increased its stake in CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after buying an additional 250 shares during the last quarter. Farrow Financial Inc. increased its stake in CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after buying an additional 270 shares during the last quarter. Kestra Private Wealth Services LLC increased its stake in CRISPR Therapeutics by 1.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after buying an additional 310 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in CRISPR Therapeutics by 7.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after buying an additional 372 shares during the last quarter. Finally, Horizon Kinetics Asset Management LLC increased its stake in CRISPR Therapeutics by 4.3% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company’s stock valued at $420,000 after buying an additional 443 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $41.86 on Friday. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of -9.58 and a beta of 1.88. The stock has a fifty day moving average of $36.83 and a 200 day moving average of $41.17. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same period in the previous year, the firm posted ($1.43) earnings per share. The company’s revenue for the quarter was up 71.6% compared to the same quarter last year. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,973 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the transaction, the chief executive officer now directly owns 180,890 shares of the company’s stock, valued at approximately $7,673,353.80. This trade represents a 5.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,953 shares of company stock valued at $736,087 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

CRSP has been the subject of several research analyst reports. The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating for the company in a research note on Thursday, May 8th. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, May 20th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Royal Bank of Canada decreased their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Finally, Truist Financial raised their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $71.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.